These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2153234)

  • 61. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
    Frangione-Beebe M; Albrecht B; Dakappagari N; Rose RT; Brooks CL; Schwendeman SP; Lairmore MD; Kaumaya PT
    Vaccine; 2000 Dec; 19(9-10):1068-81. PubMed ID: 11137241
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
    Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
    J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Kinetic and ultrastructural studies of interactions of target-sensitive immunoliposomes with herpes simplex virus.
    Ho RJ; Ting-Beall HP; Rouse BT; Huang L
    Biochemistry; 1988 Jan; 27(1):500-6. PubMed ID: 2831962
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.
    Babu JP; Pattnaik P; Gupta N; Shrivastava A; Khan M; Rao PV
    Vaccine; 2008 Aug; 26(36):4655-63. PubMed ID: 18640168
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections.
    Soleimanjahi H; Roostaee MH; Rasaee MJ; Mahboudi F; Kazemnejad A; Bamdad T; Zandi K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):100-6. PubMed ID: 16420602
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.
    Willey DE; Cantin EM; Hill LR; Moss B; Notkins AL; Openshaw H
    J Infect Dis; 1988 Dec; 158(6):1382-6. PubMed ID: 2848904
    [No Abstract]   [Full Text] [Related]  

  • 68. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein.
    Bui T; Dykers T; Hu SL; Faltynek CR; Ho RJ
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):799-806. PubMed ID: 8021814
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
    Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
    Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of herpes simplex virus 1 glycoprotein B in human cells and protection of mice against lethal herpes simplex virus 1 infection.
    Manservigi R; Negrini M; Gualandri R; Milanesi G; Barbanti-Brodano G
    Adv Exp Med Biol; 1989; 257():263-71. PubMed ID: 2559611
    [No Abstract]   [Full Text] [Related]  

  • 72. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations.
    Cappel R
    Arch Virol; 1976; 52(1-2):29-35. PubMed ID: 187150
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.
    Koff WC; Showalter SD; Hampar B; Fidler IJ
    Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants.
    Blacklaws BA; Krishna S; Minson AC; Nash AA
    Virology; 1990 Aug; 177(2):727-36. PubMed ID: 2164732
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity.
    Ho RJ; Rouse BT; Huang L
    J Biol Chem; 1987 Oct; 262(29):13973-8. PubMed ID: 2820987
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge.
    Landolfi V; Zarley CD; Abramovitz AS; Figueroa N; Wu SL; Blasiak M; Ishizaka ST; Mishkin EM
    Vaccine; 1993; 11(4):407-14. PubMed ID: 8385842
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analogues of peptide 9-21 of glycoprotein D of herpes simplex virus and their binding to group VII monoclonal antibodies.
    Welling-Wester S; Feijlbrief M; Koedijk DG; Drijfhout JW; Weijer WJ; Scheffer AJ; Welling GW
    Arch Virol; 1994; 138(3-4):331-40. PubMed ID: 7527999
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection.
    Bernstein DI; Tepe ER; Mester JC; Arnold RL; Stanberry LR; Higgins T
    Vaccine; 1999 Apr; 17(15-16):1964-9. PubMed ID: 10217595
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Potentiation of immune response against the RESA peptides of Plasmodium falciparum by incorporating a universal T-cell epitope (CS.T3) and an immunomodulator (polytuftsin), and delivery through liposomes.
    Kumar P; Biswas S; Rao DN
    Microbiol Immunol; 1999; 43(6):567-76. PubMed ID: 10480553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.